The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-expands-use-t-dxd-early-her2-breast-cancer-2026a1000g1n?src=rss
Author :
Publish date : 2026-05-18 16:02:00
Copyright for syndicated content belongs to the linked Source.
